Significats de diagnostic biomarker en anglès

Procalcitonin is currently the most promising diagnostic biomarker for sepsis.

It is a urinary diagnostic biomarker of lung and liver cancer risk and prognosis.

Our aim was to evaluate the performance of salivary a-Syn as a diagnostic biomarker of PD.

Taken together, we propose LOX as a diagnostic biomarker and a putative prognostic candidate in CMT cases.

The results of our studies showed that MCT4 could be used as an early diagnostic biomarker of HNSCC.

These results suggest that CD24 may be involved in tumor progression and can be a useful diagnostic biomarker.

These findings suggest that BDNF serum concentration may not be a reliable diagnostic biomarker to distinguish among neurodegenerative diseases.

Furthermore, Ki-67 expression was proportional to the grade of a tumour and it was a useful prognostic and diagnostic biomarker.

However, its impact on tumor development is not fully determined, and its potential as a diagnostic biomarker remains to be validated.

We conducted a critical review to summarize the evidence regarding aberrant DNA methylation patterns as a potential diagnostic biomarker predicting progression.

Taken together, miR-148b may be involved in the early stage of ovarian carcinogenesis and could be used as an efficient diagnostic biomarker.

Complete absence of class-switched B cells was a sensitive predictor of AID deficiency and should be further evaluated as a diagnostic biomarker.

BACKGROUNDClinical diagnosis of acute interstitial nephritis (AIN) is challenging because of lack of a diagnostic biomarker and requires a kidney biopsy.

These findings suggest a potential application of sE-cadherin as an alternative diagnostic biomarker for monitoring disease particularly in patients with carcinoembryonic antigen negative tumors.

Our study suggests the potential value of the gut microbiota as a diagnostic biomarker and therapeutic target for COVID-19, but further validation is needed.

However, a diagnostic biomarker and recognition of a wider spectrum of NMO presentations has expanded the patient population from which study candidates might be recruited.